Pro Medicus Ltd's stock surged 5.63% during Monday's intraday trading session following the announcement of a significant new contract.
The medical imaging technology company signed a 7-year deal worth A$90 million with Beth Israel Lahey Health, providing a substantial boost to its future revenue pipeline. The contract encompasses the company's full stack of Visage 7 products, including the Visage 7 Viewer, Visage 7 Workflow, and Visage 7 Open Archive solutions.
This major contract win represents a significant validation of Pro Medicus's technology platform and is expected to contribute meaningfully to the company's financial performance over the coming years, driving investor optimism and the stock's upward movement.